ARTH
Price
$0.25
Change
+$0.06 (+31.58%)
Updated
Jan 17 closing price
Capitalization
1.11M
BIVI
Price
$2.24
Change
+$0.01 (+0.45%)
Updated
Jan 17 closing price
Capitalization
39.8M
Ad is loading...

ARTH vs BIVI

Header iconARTH vs BIVI Comparison
Open Charts ARTH vs BIVIBanner chart's image
Arch Therapeutics
Price$0.25
Change+$0.06 (+31.58%)
Volume$5.91K
Capitalization1.11M
BioVie
Price$2.24
Change+$0.01 (+0.45%)
Volume$439.98K
Capitalization39.8M
ARTH vs BIVI Comparison Chart
Loading...
ARTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARTH vs. BIVI commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARTH is a Hold and BIVI is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (ARTH: $0.25 vs. BIVI: $2.24)
Brand notoriety: ARTH and BIVI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARTH: 73% vs. BIVI: 28%
Market capitalization -- ARTH: $1.11M vs. BIVI: $39.8M
ARTH [@Biotechnology] is valued at $1.11M. BIVI’s [@Biotechnology] market capitalization is $39.8M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARTH’s FA Score shows that 0 FA rating(s) are green whileBIVI’s FA Score has 0 green FA rating(s).

  • ARTH’s FA Score: 0 green, 5 red.
  • BIVI’s FA Score: 0 green, 5 red.
According to our system of comparison, BIVI is a better buy in the long-term than ARTH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARTH’s TA Score shows that 1 TA indicator(s) are bullish while BIVI’s TA Score has 4 bullish TA indicator(s).

  • ARTH’s TA Score: 1 bullish, 5 bearish.
  • BIVI’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, BIVI is a better buy in the short-term than ARTH.

Price Growth

ARTH (@Biotechnology) experienced а +46.97% price change this week, while BIVI (@Biotechnology) price change was +1.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

ARTH is expected to report earnings on Aug 30, 2023.

BIVI is expected to report earnings on Nov 27, 2024.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIVI($39.8M) has a higher market cap than ARTH($1.11M). ARTH YTD gains are higher at: 47.059 vs. BIVI (12.000). ARTH has higher annual earnings (EBITDA): -8.68M vs. BIVI (-23.19M). BIVI has more cash in the bank: 20M vs. ARTH (30K). BIVI has less debt than ARTH: BIVI (3.72M) vs ARTH (9.39M). ARTH has higher revenues than BIVI: ARTH (148K) vs BIVI (0).
ARTHBIVIARTH / BIVI
Capitalization1.11M39.8M3%
EBITDA-8.68M-23.19M37%
Gain YTD47.05912.000392%
P/E RatioN/AN/A-
Revenue148K0-
Total Cash30K20M0%
Total Debt9.39M3.72M253%
FUNDAMENTALS RATINGS
ARTH vs BIVI: Fundamental Ratings
ARTH
BIVI
OUTLOOK RATING
1..100
507
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
39
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6564
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BIVI's Valuation (39) in the null industry is somewhat better than the same rating for ARTH (87). This means that BIVI’s stock grew somewhat faster than ARTH’s over the last 12 months.

BIVI's Profit vs Risk Rating (100) in the null industry is in the same range as ARTH (100). This means that BIVI’s stock grew similarly to ARTH’s over the last 12 months.

BIVI's SMR Rating (100) in the null industry is in the same range as ARTH (100). This means that BIVI’s stock grew similarly to ARTH’s over the last 12 months.

BIVI's Price Growth Rating (64) in the null industry is in the same range as ARTH (65). This means that BIVI’s stock grew similarly to ARTH’s over the last 12 months.

BIVI's P/E Growth Rating (100) in the null industry is in the same range as ARTH (100). This means that BIVI’s stock grew similarly to ARTH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARTHBIVI
RSI
ODDS (%)
N/A
Bullish Trend 12 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 12 days ago
90%
Bearish Trend 12 days ago
85%
Momentum
ODDS (%)
Bearish Trend 12 days ago
90%
Bullish Trend 12 days ago
78%
MACD
ODDS (%)
Bearish Trend 12 days ago
90%
Bullish Trend 12 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 12 days ago
77%
Bullish Trend 12 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
75%
Bearish Trend 12 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 17 days ago
85%
Declines
ODDS (%)
Bearish Trend 21 days ago
90%
Bearish Trend 20 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
89%
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 12 days ago
90%
View a ticker or compare two or three
Ad is loading...
ARTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OCLGX13.590.15
+1.12%
Optimum Large Cap Growth C
DESUX23.320.23
+1.00%
DWS ESG Core Equity R6
WEECX11.290.06
+0.53%
TETON Westwood Equity A
OSGIX41.090.19
+0.46%
JPMorgan Mid Cap Growth A
EPSRX22.120.08
+0.36%
NYLI Epoch Global Equity Yield Class R6

ARTH and

Correlation & Price change

A.I.dvisor tells us that ARTH and EDSA have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ARTH and EDSA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARTH
1D Price
Change %
ARTH100%
+28.21%
EDSA - ARTH
21%
Poorly correlated
+0.60%
HRMY - ARTH
20%
Poorly correlated
+1.32%
BIVI - ARTH
13%
Poorly correlated
+0.45%
APLIF - ARTH
12%
Poorly correlated
N/A
BETRF - ARTH
5%
Poorly correlated
-10.67%
More

BIVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIVI has been loosely correlated with HOFBF. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BIVI jumps, then HOFBF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIVI
1D Price
Change %
BIVI100%
+0.45%
HOFBF - BIVI
44%
Loosely correlated
N/A
HURA - BIVI
42%
Loosely correlated
+1.27%
SCNI - BIVI
34%
Loosely correlated
-1.54%
BIORQ - BIVI
34%
Loosely correlated
-14.21%
PRME - BIVI
27%
Poorly correlated
+0.70%
More